Medicine and Dentistry
Combination Therapy
100%
Biological Marker
100%
Immune Checkpoint Blockade
100%
Therapeutic Procedure
85%
Patient
42%
Programmed Death-Ligand 1
42%
Neoplasm
28%
Therapeutics
28%
Malignant Neoplasm
14%
Triple Negative Breast Cancer
14%
Personalized Medicine
14%
Radiation Therapy
14%
Clinician
14%
Immunocompetent Cell
14%
Solid Malignant Neoplasm
14%
Biomarker Study
14%
CTLA-4
14%
Cancer Immunotherapy
14%
Patient Selection
14%
Immune-Related Adverse Events
14%
Paclitaxel
14%
Pembrolizumab
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Combination Therapy
100%
Malignant Neoplasm
40%
Neoplasm
40%
Biomarker Study
20%
Cytotoxic T Lymphocyte Antigen 4
20%
Solid Malignant Neoplasm
20%
Adverse Event
20%
Triple Negative Breast Cancer
20%
Paclitaxel
20%
Pembrolizumab
20%
Immunotherapy
20%
Immunology and Microbiology
Immune Checkpoint Blockade
100%
Programmed Death-Ligand 1
42%
Pembrolizumab
14%
Breast
14%
Immunocompetent Cell
14%
Solid
14%
Staining
14%
CTLA-4
14%
Cancer Immunotherapy
14%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
PD-L1
37%
Solid
12%
Biomarker Study
12%
Immunocompetent Cell
12%
Staining
12%
Albumin
12%
Cancer Immunotherapy
12%
Pembrolizumab
12%
CTLA-4
12%
Material Science
Tumor
100%
Solid
33%
Nanoparticle
33%